Proton or Photon Radiation?
Published on February 25, 2020 Background Many people with locally advanced cancers are treated with a combination of chemotherapy and either photon or proton radiation.
Metastatic Renal Cell Cancer, mRCC – Promising Treatment Option with Keytruda + Avastin
Published on February 25, 2020 Background This phase Ib/II study was designed to evaluate the safety and efficacy of a novel immunotherapy and VEGF-directed therapy
Breakthrough Data of DPX-Survivac immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
Published on February 26, 2020 Background In heavily pretreated patients, for whom there remains a tremendous unmet need with limited options beyond single-agent chemotherapy, which
CAR-T cell therapy brings new hope for Mesothelioma patients but is hard to get
Background While standard protocols such as chemotherapy are still widely used, clinical trials are supporting the discovery of new treatments and some have proven to
Kidney cancer – Novel drug shows promise in advanced disease
Published on February 15, 2020 Background Scientists report promising activity of the novel an oral first-in-class MK-6482 drug that targets a key driver of clear
A New Targeted Therapy Pill Extends Lives of Patients with Metastatic Renal Cell Carcinoma, RCC
Background In the phase III trial, more than 300 patients with metastatic RCC were randomly chosen to receive Fotivda (Tivozanib) or Nexavar (Sorafenib) for a
Gastric Cancer – 83.7% respond to Opdivo with Taxol plus Cyramza
The triplet of Opdivo, Cyramza and Paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.
Faslodex + Capivasertib vs Placebo in Metastatic, ER positive Breast Cancer
Published February 5, 2020 Background Capivasertib (AZD5363) is an oral inhibitor of AKT and by that it influences cell division, apoptosis and cell metabolism. The
Promising efficacy with a new combination of 2 approved drugs – Lenvima plus Keytruda
Published on January 21, 2020 Background In this trial, 137 cancer patients with NO AVAILABLE STANDARD THERAPEUTIC OPTIONS were treated with the combination of Lenvima
This morning! We obtained consent of the pharmaceutical company to provide compassionate drug to metastatic lung cancer patient
Background – A woman in her sixties was diagnosed about two years ago with Small Cell Lung Cancer, SCLC (15% of all lung cancer patients
That’s our power! A 38 y.o. cancer patient will receive a promising compassionate drug
Background – 6 months ago, M.N., 38, was diagnosed with an extremely rare and aggressive type of cancer. A cancer that progresses tremendously rapidly in
GBM or DIPG – This is how ONC201 can be obtained as compassion
Intended for recurrent Glioblastoma, GBM, patients or patients with DIPG brain tumor with H3 K27M mutation We will be happy to help you access the
